Home›Research›Compare›Angiotensin (1-7) vs Sermorelin
Peptide ComparisonAngiotensin (1-7) vs Sermorelin
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
Sermorelin
GHRH 1-29
Half-life: 10–20 minutes
445 providers listed
Angiotensin (1-7) and Sermorelin target different goals — Angiotensin (1-7) for cardiovascular protection, Sermorelin for pulsatile GH release via direct GHRH receptor agonism at the pituitary. They're compared here for reference, not as direct substitutes.
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
Sermorelin
Evidence
Half-life
10–20 minutes
Angiotensin (1-7) and Sermorelin target different goals — Angiotensin (1-7) for Longevity & Cellular, Sermorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Angiotensin (1-7)
Sermorelin
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
Sermorelin
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodyb…
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients…
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostat…
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About Sermorelin
Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Sermorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Sermorelin clinical protocols measure IGF-1 as the primary marker of GH axis response. Fasting glucose and insulin are standard baseline assessments given GH's effect on insulin sensitivity.
Sermorelin
Ipamorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
Angiotensin (1-7)
Not enough vendor pricing yet.
Sermorelin
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringSermorelin
445 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Angiotensin (1-7) vs Sermorelin — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/sermorelin